Drug Trial Radar · NCT04043806
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
Last checked: Nov 19, 2026Latest source record: Jul 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
458
Actual
Start
Aug 9, 2019
Primary completion
Dec 14, 2022
Study completion Dec 14, 2022
Sponsor
- Lead sponsor
- Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
- Sponsor type
- Industry
- First posted
- Aug 2, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study evaluated the long-term safety and tolerability of elexacaftor (ELX), tezacaftor (TEZ), and ivacaftor (IVA) triple combination (TC) treatment in participants with cystic fibrosis (CF).
Conditions
- Cystic Fibrosis
Interventions
ELX/TEZ/IVADrug
Fixed-dose combination (FDC) tablet for oral administration.
IVADrug
Tablet for oral administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: From Baseline through Week 100
Locations
97 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Stanford University
Palo Alto, California
Children's Hospital Colorado
Aurora, Colorado
Hartford Hospital
Hartford, Connecticut
Yale New Haven Hospital
New Haven, Connecticut
University of Miami Miller School of Medicine
Miami, Florida
Nicklaus Children's Hospital
Miami, Florida
Arnold Palmer Hospital Pulmonary and Sleep Medicine
Orlando, Florida
Johns Hopkins All Children's Hospital Outpatient Care Center
St. Petersburg, Florida
St. Luke's CF Center of Idaho
Boise, Idaho
Cystic Fibrosis Institute
Glenview, Illinois
Advocate Children's Hospital - Park Ridge / North Suburban Pulmonary and Critical Care Consultants
Niles, Illinois
Indiana University
Indianapolis, Indiana
The University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kentucky
Lexington, Kentucky
Kosair Charities Pediatric Clinical Research Unit
Louisville, Kentucky
Johns Hopkins Hospital
Baltimore, Maryland
Boston Children's Hospital
Boston, Massachusetts
UMass Memorial Medical Center
Worcester, Massachusetts
Michigan Medicine
Ann Arbor, Michigan
University of Minnesota
Minneapolis, Minnesota
University of Mississippi Medical Center
Jackson, Mississippi
The Children's Mercy Hospital
Kansas City, Missouri
Washington University School of Medicine / St. Louis Children's Hospital
St Louis, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Rutgers Robert Wood Johnson Medical School
New Brunswick, New Jersey
Albany Medical College, Pulmonary and Critical Care Medicine
Albany, New York
Lung and Cystic Fibrosis Center at Women and Children's Hospital of Buffalo
Buffalo, New York
Northwell Health- Long Island Jewish Medical Center
New Hyde Park, New York
Columbia University Medical Center
New York, New York
SUNY Upstate Medical University
Syracuse, New York
Clinical Research of Charlotte
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Santiago Reyes, M.D.
Oklahoma City, Oklahoma
Oregon Health & Science University
Portland, Oregon
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Sanford Children's Speciality Clinic
Sioux Falls, South Dakota
University of Tennessee Medical Center
Knoxville, Tennessee
Children's Foundation Research Center / Le Bonheur Children's Hospital
Memphis, Tennessee
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.